COMPANY NEW

October 5, 2020

CureLab Oncology Receives Pre-IND Response from FDA Regarding Planned Trial for Triple Negative Breast Cancer

Feedback from FDA was constructive and includes recommendations to test cumulative toxicity and clinical benefits progression; this has led the company to consider a shorter trial design for Phase II.
April 29, 2020

CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?

Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over